| Exploiting cancer cell cycling for selective protection of normal cells. | |
| | |
MedLine Citation:
|
PMID: 11389048 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Chemotherapy of cancer is limited by its toxicity to normal cells. On the basis of discoveries in signal transduction and cell cycle regulation, novel mechanism-based therapeutics are being developed. Although these cell cycle modulators were designed to target cancer cells, some of them can also be applied for a different purpose, i.e., to protect normal cells against the lethality of chemotherapy. Loss of sensitivity of cancer cells to cell cycle inhibitors can be exploited for selective protection of normal cells that retain this response. Indeed, inhibition of redundant or overactivated pathways (e.g., growth factor-activated pathways) or stimulation of absent pathways in cancer cells (e.g., p53, Rb, and p16) may not arrest cycling of cancer cells. But growth arrest of normal cells will then permit selective killing of cancer cells by cycle-dependent chemotherapy. |
| | |
Authors:
|
M V Blagosklonny; A B Pardee |
Related Documents
:
|
11119718 - Analysis of fak-associated signaling pathways in the regulation of cell cycle progression. 12170768 - Duplication of the genome in normal and cancer cell cycles. 18418078 - Oxidative stress induces cell cycle-dependent mre11 recruitment, atm and chk2 activatio... 6542178 - Cinematographic study of the effects of cis-diammine-dichloroplatinum on mouse l cells. 22449708 - Sodium selenite-induced activation of dapk promotes autophagy in human leukemia hl60 ce... 479318 - Blue light-induced, intrinsic vacuolar fluorescence in onion guard cells. |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review |
Journal Detail:
|
Title: Cancer research Volume: 61 ISSN: 0008-5472 ISO Abbreviation: Cancer Res. Publication Date: 2001 Jun |
Date Detail:
|
Created Date: 2001-06-04 Completed Date: 2001-06-21 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 2984705R Medline TA: Cancer Res Country: United States |
Other Details:
|
Languages: eng Pagination: 4301-5 Citation Subset: IM |
Affiliation:
|
Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA. mikhailb@box-m.nih.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents / adverse effects, pharmacology* Cell Cycle / drug effects*, physiology* Cell Division / drug effects Humans Neoplasms / drug therapy*, pathology* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia an...
Next Document: Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis.